Potential medicinal plants for CNS disorders: An overview

Phytotherapy Research

Volumn 20, Issue 12, 2006, Pages 1023-1035

  Kumar, Vikas ^a,b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

Alzheimer's disease; Anxiety; CNS disorders; Depression; Medicinal plants; Stress

Indexed keywords

BACOPA MONNIERI EXTRACT; BILOBALIDE; CHOLINESTERASE INHIBITOR; CONVOLVULUS PLURICAULIS EXTRACT; GALANTAMINE; GINKGO BILOBA EXTRACT; GINKGOLIDE B; HYPERFORIN; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; KAVA EXTRACT; PHENYTOIN; PLANT EXTRACT; RIVASTIGMINE; VALERIAN;

ALZHEIMER DISEASE; ANXIETY DISORDER; AYURVEDA; BACOPA MONNIERI; BRAIN HYPOXIA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONVOLVULUS; DEMENTIA; DEPRESSION; DRUG BINDING; DRUG MECHANISM; GINKGO BILOBA; HUMAN; HYPERICUM PERFORATUM; MEDICINAL PLANT; NEUROPROTECTION; PIPER METHYSTICUM; REVIEW; SLEEP DISORDER; UNSPECIFIED SIDE EFFECT; VALERIANA;

ANGIOSPERMS; CENTRAL NERVOUS SYSTEM DISEASES; GINKGO BILOBA; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL;

BACOPA MONNIERI; CONVOLVULUS; GINKGO BILOBA; PIPER METHYSTICUM; VALERIANA;

EID: 33845671730     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.1970     Document Type: Review

References (236)

1. Abourashed EA, Koetter U, Brattstrom A. 2004. In vitro binding experiments with a Valerian, hops and their fixed combination extract (Ze91019) to selected central nervous system receptors. Phytomedicine 11: 633-638.
2. Abraham KC, Connor KM, Davidson JR. 2004. Explanatory attributions of anxiety and recovery in a study of kava. J Altern Complement Med 10: 556-559.
3. Achliya GS, Wadodkar SG, Dorle AK. 2004. Evaluation of sedative and anticonvulsant activities of Unmadnashak Ghrita. J Ethnopharmacol 94: 77-83.
4. Ahlemeyer B, Krieglstein J. 2003a. Neuroprotective effects of Ginkgo biloba extract. Cell Mol Life Sci 60: 1779-1792.
5. Ahlemeyer B, Krieglstein J. 2003b. Pharmacological studies supporting the therapeutic use of Ginkgo biloba extract for Alzheimer's disease. Pharmacopsychiatry 36: 8-14.
6. Anbarasi K, Vani G, Balakrishna K, Devi CS. 2005a. Effect of bacoside A on membrane-bound ATPases in the brain of rats exposed to cigarette smoke. J Biochem Mol Toxicol 19: 59-65.
7. Anbarasi K, Vani G, Balakrishna K, Devi CS. 2005b. Creatine kinase isoenzyme patterns upon chronic exposure to cigarette smoke: protective effect of bacoside A. Vascul Pharmacol 42: 57-61.
8. Anbarasi K, Vani G, Devi CS. 2005c. Protective effect of bacoside A on cigarette smoking-induced brain mitochondrial dysfunction in rats. J Environ Pathol Toxicol Oncol 24: 225-234.
9. Andreatini R, Sartori VA, Seabra ML, Leite JR. 2002. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res 16: 650-654.
10. Andrieu S, Gillette S, Amouyal K et al. 2003. Association of Alzheimer's disease onset with Ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J Gerontol A Biol Sci Med Sci 58: 372-377.
11. Anke J, Ramzan I. 2004a. Kava hepatotoxicity: Are we any closer to the truth? Planta Med 70: 193-196.
12. Anke J, Ramzan I. 2004b. Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.). J Ethnopharmacol 93: 153-160.
13. Auster F, Schaefer J. 1958. Valeriana officinalis L., Arzneipflanzen. G. Thieme: Lepzig.
14. Bafna PA, Balaraman R. 2005. Antioxidant activity of DHC-1, an herbal formulation, in experimentally-induced cardiac and renal damage. Phytother Res 19: 216-221.
15. Barnett SD, Connor KM, Davidson JR. 2001. The self-assessment of resilience and anxiety: psychometric properties. CNS Spectr 10: 854-857.
16. Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, Quirion R. 2000. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci 12: 1882-1890.
17. Beaubrun G, Gray GE. 2000. A review of herbal medicines for psychiatric disorders. Psychiatr Serv 51: 1130-1134.
18. Bhattacharya SK, Bhattacharya A, Kumar A, Ghosal S. 2000c. Antioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampus. Phytother Res 14: 174-179.
19. Bhattacharya SK, Chakrabarti A, Chatterjee SS. 1998a. Activity profiles of two hyperforin-containing Hypericum extracts in behavioural models. Pharmacopsychiatry 31: 22-29.
20. Bhattacharya SK, Ghosal S. 1998b. Anxiolytic activity of a standardized extract of Bacopa monniera: an experimental study. Phytomedicine 5: 77-82.
21. Bhattacharya SK, Kumar A, Ghosal S. 1999. Effect of Bacopa monniera on animal models of Alzheimer's disease and perturbed central cholinergic markers of cognition in rats. In Molecular Aspects of Asian Medicines, Siva Sankar DV (ed.). PJD Publications: New York.
22. Biber A, Fischer H, Romer A, Chatterjee SS. 1998. Oral bioavailability of hyperforin from Hypericum extracts in rats and human volunteers. Pharmacopsychiatry 31: 36-43.
23. Birks J, Grimley EV, Van Dongen M. 2002. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 4: CD003120.
24. Blumenthal M, Busse WR, Goldberg A et al. (eds), Klein S and Rister RS, trans. 1998. The Complete German Commission E Monographs. American Botanical Council: Austin, TX, 156.
25. Bodo A, Bakos E, Szeri F. 2003. The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett 141: 133-143.
26. Bombardelli E, Morazzoni P. 1995. Hypericum perforatum. Fitoterapia 66: 43-68.
27. Boonkaew T, Camper ND. 2005. Biological activities of Ginkgo extracts. Phytomedicine 12: 318-323.
28. Boralle E, Braquet P, Gottlieb. 1988. A review of its chemical composition. In Ginkgolides Chemistry, Biology, Pharmacology and Clinical Perspective. Vol 1. JP Process Science Publishers: Barcelona, Spain, 9-25.
29. Brown RP, Gerbarg PL. 2001. Herbs and nutrients in the treatment of depression, anxiety, insomnia, migraine, and obesity. J Psychiatr Pract 7: 75-91.
30. Buchholzer ML, Dvorak C, Chatterjee SS, Klein J. 2002. Dual modulation of striatal acetylcholine release by hyperforin, a constituent of St. John's wort. J Pharmacol Exp Ther 301: 714-719.
31. Butterweck V, Christoffel V, Nahrstedt A, Petereit F, Spengler B, Winterhoff H. 2003. Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models. Life Sci 73: 627-639.
32. Capasso A, Sorrentino L. 2005. Pharmacological studies on the sedative and hypnotic effect of Kava kava and Passiflora extracts combination. Phytomedicine 12: 39-45.
33. Carrigan D. 1995. Fossil medicine - Ginkgo biloba. Eur J Herbal Med 1: 16-18.
34. Cervo L, Rozio M, Ekalle-Soppo CB, Guiso G, Morazzoni P, Caccia S. 2002. Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts. Psychopharmacol (Berl) 164: 423-428.
35. Challem J. 2001. St. John's wort vs drugs. Nutr Sci News 6: 212-218.
36. Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Muller WE. 1998a. Hyperforin as a possible antidepressant component of Hypericum extracts. Life Sci 63: 499-510.
37. Chatterjee SS, Doelman CJ, Noldner M, Biber A, Koch E. 2005. Influence of the Ginkgo extract EGb 761 on rat liver cytochrome P450 and steroid metabolism and excretion in rats and man. J Pharm Pharmacol 57: 641-650.
38. Chatterjee SS, Kondratskaya EL, Krishtal OA. 2003. Structure-activity studies with Ginkgo biloba extract constituents as receptor-gated chloride channel blockers and modulators. Pharmacopsychiatry 36: S68-S77.
39. Chatterjee SS, Noldner M, Koch E, Erdelmeier C. 1998b. Antidepressant activity of Hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry 31: 7-15.
40. Chatterjee SS, Nöldner M. 1997. Losigamone: From plant extract to antiepileptic drug. CNS Drug Rev 3: 225-244.
41. Chopra RN, Nayar SL, Chopra IC. 1956. Glossary of Indian Medicinal Plants. Council of Scientific and Industry Research: New Delhi, 32.
42. Chowdhuri DK, Parmar D, Kakkar P, Shukla R, Seth PK, Srimal RC. 2002. Antistress effects of bacosides of Bacopa monnieri: modulation of Hsp70 expression, superoxide dismutase and cytochrome P450 activity in rat brain. Phytother Res 16: 639-645.
43. Clough AR, Bailie RS, Currie B. 2003. Liver function test abnormalities in users of aqueous kava extracts. J Toxicol Clin Toxicol 41: 821-829.
44. Colciaghi F, Borroni B, Zimmermann M et al. 2004. Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiol Dis 16: 454-460.
45. Connor KM, Davidson JR, Churchill LE. 2001. Adverse-effect profile of kava. CNS Spectr 6: 850-853.
46. Cote CS, Kor C, Cohen J, Auclair K. 2004. Composition and biological activity of traditional and commercial kava extracts. Biochem Biophys Res Commun 10: 147-152.
47. Cragg GM, Newman DJ, Sanders KM. 1997. Natural products in drug discovery and development. J Nat Prod 60: 52-60.
48. Cropley M, Cave Z, Ellis J, Middleton RW. 2002. Effect of kava and valerian on human physiological and psychological responses to mental stress assessed under laboratory conditions. Phytother Res 16: 23-27.
49. Cunningham S. 1991. Encyclopedia of Magical Herbs. Lewellyn Publications: St Paul, 133.
50. Dandekar UP, Chandra RS, Dalvi SS et al. 1992. Analysis of a clinically important interaction between phenytoin and Shankhapushpi, an Ayurvedic preparation. J Ethnopharmacol 35: 285-288.
51. Daniel K. 1935. Johanniskraut (Hypericum perforatum) bei psychische Störungen. Hippokrates 10: 929-932.
52. Das A, Shanker G, Nath C, Pal R, Singh S, Singh H. 2002. A comparative study in rodents of standardized extracts of Bacopa monniera and Ginkgo biloba: anticholinesterase and cognitive enhancing activities. Pharmacol Biochem Behav 73: 893-900.
53. Dave UP, Chauvan V, Dalvi J. 1993. Evaluation of BR-16 A (Mentat) in cognitive and behavioural dysfunction of mentally retarded children: a placebo-controlled study. Indian J Pediatr 60: 423-428.
54. Diaper A, Hindmarch I. 2004. A double-blind, placebo-controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleep-disturbed older adults. Phytother Res 18: 831-836.
55. Dietz BM, Mahady GB, Pauli GF, Farnsworth NR. 2005. Valerian extract and valerenic acid are partial agonists of the 5-HT(5a) receptor in vitro. Brain Res Mol Brain Res 138: 191-197.
56. Dominguez RA, Bravo-Valverde RL, Kaplowitz BR, Cott JM. 2000. Valerian as a hypnotic for Hispanic patients. Cultur Divers Ethnic Minor Psychol 6: 84-92.
57. Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I. 2000. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry 33: 47-53.
58. Dorababu M, Prabha T, Priyambada S, Agrawal VK, Aryya NC, Goel RK. 2004. Effect of Bacopa monniera and Azadirachta indica on gastric ulceration and healing in experimental NIDDM rats. Indian J Exp Biol 42: 389-397.
59. Drewe J. 2000. Mechanisen der Interaktionen mit Johanniskraut [Abstract]. In Phytopharmaka VI Forschung und Klinsche Anwendung. Deutsche Gesellschaft fur Klinische Pharmakologie und Therapie: Berlin.
60. Eckert GP, Keller JH, Jourdan C et al. 2004. Hyperforin modifies neuronal membrane properties in vivo. Neurosci Lett 367: 139-143.
61. Enz A, Amstutz R, Boddeke H et al. 1993. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog Brain Res 98: 431-438.
62. Ernst E (ed.). 2003a. In Hypericum. The genus Hypericum. Medicinal and Aromatic Plants-Industrial Profiles Series, Hardman R (series ed), Taylor & Francis: London and New York.
63. Ernst E. 1999. Second thoughts about safety of St John's wort. Lancet 354: 2014-2016.
64. Ernst E. 2002. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med 136: 42-53.
65. Ernst E. 2003b. Herb-drug interactions: not a clinically relevant risk. Focus Alter Complem Ther 8: 189.
66. Evans JG, Wilcock G, Birks J. 2004. Evidence-based pharmacotherapy of Alzheimer's disease. Int J Neuropsychopharmacol 7: 351-369.
67. Feltenstein MW, Lambdin LC, Ganzera M et al. 2003. Anxiolytic properties of Piper methysticum extract samples and fractions in the chick social-separation-stress procedure. Phytother Res 17: 210-216.
68. Fernandez S, Wasowski C, Paladini AC, Marder M. 2004. Sedative and sleep-enhancing properties of linarin, a flavonoid-isolated from Valeriana officinalis. Pharmacol Biochem Behav 77: 399-404.
69. Fugh-Berman A, Ernst E. 2001. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 52: 587-595.
70. Fussel A, Wolf A, Brattstrom A. 2000. Effect of a fixed valerian-Hop extract combination (Ze 91019) on sleep polygraphy in patients with non-organic insomnia: a pilot study. Eur J Med Res 5: 385-390.
71. Ganguly DK, Malhotra CL. 1967. Some behavioural effects of an active fraction from Herpestis monniera, Linn. (Brahmi). Indian J Med Res 55: 473-482.
72. Ganju L, Karan D, Chanda S, Srivastava KK, Sawhney RC, Selvamurthy W. 2003. Immunomodulatory effects of agents of plant origin. Biomed Pharmacother 57: 296-300.
73. Gasser US, Gasser T. 2001. Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko. MMW Fortschr Med 143: 40-41.
74. Gaster B, Holroyd J. 2000. St. John's wort for depression: a systemic review. Arch Int Med 160: 152-156.
75. Geier FP, Konstantinowicz T. 2004. Kava treatment in patients with anxiety. Phytother Res 18: 297-300.
76. Gertz HJ, Kiefer M. 2004. Review about Ginkgo biloba special extract EGb 761 (Ginkgo). Curr Pharm Des 10: 261-264.
77. Ghosh S, Kar SK. 1966. Clinical trial on Brahmi. II. Psychological investigation with normals. J Exp Med Sci 10: 12-13.
78. Goel RK, Sairam K, Babu MD, Tavares IA, Raman A. 2003. In vitro evaluation of Bacopa monniera on anti-Helicobacter pylori activity and accumulation of prostaglandins. Phytomedicine 10: 523-527.
79. Haan J, Horr R. 2004. Delay in progression of dependency and need of care of dementia patients treated with Ginkgo special extract EGb 761. Wien Med Wochenschr 154: 511-514.
80. Hadley S, Petry JJ. 2003. Valerian. Am Fam Physician 67: 1755-1758.
81. Hallam KT, Olver JS, McGrath C, Norman TR. 2003. Comparative cognitive and psychomotor effects of single doses of Valeriana officianalis and triazolam in healthy volunteers. Hum Psychopharmacol 18: 619-625.
82. Hendriks H, Bos R, Allersma DP, Malingre TM, Koster AS. 1981. Pharmacological screening of valerenal and some other components of essential oil of Valeriana officinalis. Planta Med 42: 62-68.
83. Houghton PJ. 1999. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol 51: 505-512.
84. Hu Z, Yang X, Ho PC et al. 2005. Herb-drug interactions: a literature review. Drugs 65: 1239-1282.
85. Indurwade NH, Biyani KR. 2000. Evaluation of comparative and combined depressive effect of Brahmi, Shankhpushpi and Jatamansi in mice. Indian J Med Sci 54: 339-341.
86. Izzo AA. 2004. Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther 42: 139-148.
87. Izzo AA, Ernst E. 2001. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 61: 2163-2175.
88. Jain P, Khanna NK, Trehan T, Pendse VK, Godhwani JL. 1994. Antiinflammatory effects of an Ayurvedic preparation, Brahmi Rasayan, in rodents. Indian J Exp Biol 32: 633-636.
89. Jorm AF, Christensen H, Griffiths KM, Parslow RA, Rodgers B, Blewitt KA. 2004a. Effectiveness of complementary and self-help treatments for anxiety disorders. Med J Aust 181: 529-46.
90. Jorm AF, Rodgers B, Christensen H. 2004b. Use of medications to enhance memory in a large community sample of 60-64 year olds. Int Psychogeriatr 16: 209-217.
91. Kanowski S, Hoerr R. 2003. Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multicenter, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry 36: 297-303.
92. Käufeler R, Meier B, Brattström A. 2001. Efficacy and tolerability of Ze117 St. John's wort extract in comparison with placebo, imipramine and fluoxetine for the treatment of mild to moderate depression according to ICD-10. An overview. Pharmacopsychiatry 34: S49-S50.
93. Kidd PM. 1999. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. Altern Med Rev 4: 144-161.
94. Kiewert C, Buchholzer ML, Hartmann J, Chatterjee SS, Klein J. 2004. Stimulation of hippocampal acetylcholine release by hyperforin, a constituent of St. John's Wort. Neurosci Lett 364: 195-198.
95. Kishore K, Singh M. 2005. Effect of bacosides, alcoholic extract of Bacopa monniera Linn. (brahmi), on experimental amnesia in mice. Indian J Exp Biol 43: 640-645.
96. Kleijnen J, Knipschild P. 1992. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol 34: 352-358.
97. Klein J, Chatterjee SS, Loffelholz K. 1997. Phospholipid breakdown and choline release under hypoxic conditions: inhibition by bilobalide, a constituent of Ginkgo biloba. Brain Res 755: 347-350.
98. Klein J, Weichel O, Hilgert M, Rupp J, Chatterjee SS, Nawrath H. 2003. Excitotoxic hippocampal membrane breakdown and its inhibition by bilobalide: role of chloride fluxes. Pharmacopsychiatry 36: S78-83.
99. Klusa V, Germane S, Noldner M, Chatterjee SS. 2001. Hypericum extract and hyperforin: memory-enhancing properties in rodents. Pharmacopsychiatry 34: S61-S69.
100. Koch E. 2005. Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts. Phytomedicine 12: 10-16.
101. Kondratskaya EL, Fisyunov AI, Chatterjee SS, Krishtal OA. 2004a. Ginkgolide B preferentially blocks chloride channels formed by heterorneric glycine receptors in hippocampal pyramidal neurons of rat. Brain Res Bull 63: 309-314.
102. Kondratskaya EL, Pankratov YV, Lalo UV, Chatterjee SS, Krishtal OA. 2004b. Inhibition of hippocampal LTP by ginkgolide B is mediated by its blocking action on PAF rather than glycine receptors. Neurochem Int 44: 171-177.
103. Krystal AD, Ressler I. 2001. The use of valerian in neuropsychiatry. CNS Spectr 6: 841-847.
104. Kumar V, Jaiswal AK, Singh PN, Bhattacharya SK. 2000a. Anxiolytic activity of Indian Hypericum perforatum Linn: an experimental study. Indian J Exp Biol 38: 36-41.
105. Kumar V, Khanna VK, Seth PK, Singh PN, Bhattacharya SK. 2002. Brain neurotransmitter receptor binding and nootropic studies on Indian Hypericum perforatum Linn. Phytother Res 16: 210-216.
106. Kumar V, Kiewert C, Klein J. 2005. Hyperforin inhibits NMDA-induced edema in hippocampal slices. Poster # T3283 presented at American Association of Pharmaceutical Scientist's annual meeting and exposition, Nashville, TN, USA, November 6-10.
107. Kumar V, Mazinarishvili A, Kiewert C, Abbruscato T, Bickel U, Schyf CJ, Klein J. 2006. NMDA receptor-antagonistic properties of hyperforin, a constituent of St. John's work. J Pharmacol Sci: In press.
108. Kumar V, Singh PN, Bhattacharya SK. 2000b. Hypericum perforatum: nature's mood stabilizer. Indian J Exp Biol 38: 1077-1085.
109. Kumar V, Singh PN, Bhattacharya SK. 2001a. Anti-inflammatory and analgesic activity of Indian Hypericum perforatum L. Indian J Exp Biol 39: 339-343.
110. Kumar V, Singh PN, Bhattacharya SK. 2001b. Anti-stress activity of Indian Hypericum perforatum Linn. Indian J Exp Biol 39: 344-349.
111. Kumar V, Singh PN, Bhattacharya SK. 2001c. Neurochemical studies on Indian Hypericum perforatum Linn. Indian J Exp Biol 39: 334-338.
112. Kumar V, Singh PN, Bhattacharya SK. 2003. Neuropsychopharmacological studies on Indian Hypericum perforatum Linn. In Medicinal and Aromatic Plants - Industrial Profile. Volume Genus Hypericum, Ernst E (ed.), 1st edn. Taylor & Francis: London and simultaneously published by Taylor & Francis: New York, USA and Canada, 179-226.
113. Kumar V, Singh PN, Jaiswal AK, Bhattacharya SK. 1999. Antidepressant activity of Indian Hypericum perforatum Linn in rodents. Indian J Exp Biol 37: 1171-1176.
114. Kumar V, Singh PN, Muruganandam AV, Bhattacharya SK. 2000c. Effect of Indian Hypericum perforatum Linn on animal models of cognitive dysfunction. J Ethnopharmacol 72: 119-128.
115. Kurz A, Van Baelen B. 2004. Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the Cochrane collaboration. Dement Geriatr Cogn Disord 18: 217-226.
116. Laakmann G, Schule C, Baghai T, Kieser M. 1998. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 31: 54-59.
117. Larzelere MM, Wiseman P. 2002. Anxiety, depression, and insomnia. Prim Care 29: 339-360.
118. Le Bars PL. 2003. Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles. Pharmacopsychiatry 36: 50-55.
119. Leathwood PD, Chauffard F. 1985. Aqueous extract of valerian reduces latency to fall asleep in man. Planta Med 4: 144-148.
120. Leathwood PD, Chauffard F, Heck E, Munoz-Box R. 1982. Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav 17: 65-71.
121. Lee TF, Chen CF, Wang LC. 2004. Effect of ginkgolides on beta-amyloid-suppressed acetylcholine release from rat hippocampal slices. Phytother Res 18: 556-560.
122. Lehmann E, Kinzler E, Friedemann J. 1996. Efficacy of a special Kava extract (Piper methysticum) in patients with states of anxiety, tension and excitedness of non-mental origin - A double-blind placebo-controlled study of four weeks treatment. Phytomedicine 3: 113-119.
123. Lewin L. 1886. Uber Piper methysticum (Kawa). A Hirschwald: Berlin.
124. Lindahl O, Lindwall L. 1989. Double blind study of a valerian preparation. Pharmacol Biochem Behav 32: 1065-1066.
125. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. 1996. St John's wort for depression - an overview and meta-analysis of randomised clinical trials. Br Med J 313: 253-258.
126. Maher BF, Stough C, Shelmerdine A, Wesnes K, Nathan PJ. 2002. The acute effects of combined administration of Ginkgo biloba and Bacopa monniera on cognitive function in humans. Hum Psychopharmacol 17: 163-164.
127. Malhotra CL, Das PK. 1959. Pharmacological studies of Herpestis monniera Linn. (Brahmi). Indian J Med Res 47: 294-305.
128. Mannel M. 2004. Drug interactions with St John's wort. Drug Safety 27: 773-797.
129. Marsh WL, Davies JA. 2002. The involvement of sodium and calcium ions in the release of amino acid neurotransmitters from mouse cortical slices elicited by hyperforin. Life Sci 71: 2645-2655.
130. Martis G, Rao A. 1992. Neuropharmacological activity of Herpestis monniera. Fitoterapia 63: 399-404.
131. Martis G, Rao A, Karanth KS. 1992. Neuropharmaological activity of Herpestis monniera. Fitoterapia 63: 399-404.
132. Medina JH, Pena C, Levi de Stein M, Wolfman C, Paladini AC. 1989. Benzodiazepine-like molecules, as well as other ligands for the brain benzodiazepine receptors, are relatively common constituents of plants. Biochem Biophys Res Commun 165: 547-553.
133. Michel PF, Hosford D. 1988. Ginkgo biloba: From 'Living Fossil' to Modern Therapeutic Agent. In Ginkgolled-Chemistry, Biology, Pharmacology and Clinical Perspectives, Braquet P (ed.). Vol 1. JP Process Publishers: Barcelona, Spain, 1-8.
134. Mills E, Montori VM, Wu P, Gallicano K, Clarke M, Guyatt G. 2004. Interaction of St John's wort with conventional drugs: systematic review of clinical trials. Br Med J 329: 27-30.
135. Mix JA, Crews WD Jr. 2002. A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Hum Psychopharmacol 17: 267-277.
136. Mkrtchyan A, Panosyan V, Panossian A, Wikman G, Wagner H. 2005. A phase I clinical study of Andrographis paniculata fixed combination Kan Jang versus ginseng and valerian on the semen quality of healthy male subjects. Phytomedicine 12: 403-409.
137. Mukherjee GD, Dey CD. 1966. Clinical trial on Brahmi. I. J Exp Med Sci 10: 5-11.
138. Muller T, Mannel M, Murck H, Rahlfs VW. 2004b. Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial. Psychosom Med 66: 538-547.
139. Muller WE. 2003. Current St John's wort research from mode of action to clinical efficacy. Pharmacol Res 47: 101-109.
140. Muller WE (ed.). 2005. In St. John's Wort and its Active Principles in Depression and Anxiety. Milestones in Drug Therapy Series, Parnham MJ, Bruinvels J (series eds). Springer: Germany.
141. Muller WE, Chatterjee SS. 2003. Cognitive and other behavioral effects of EGb 761 in animal models. Pharmacopsychiatry 36: 24-31.
142. Muller WE, Singer A, Wonnemann M, Hafner U, Rolli M, Schafer C. 1998. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract. Pharmacopsychiatry 31: 16-21.
143. Nakanishi K. 2005. Terpene trilactones from Gingko biloba: From ancient times to the 21st century. Bioorg Med Chem 13: 4987-5000.
144. Nathan PJ, Clarke J, Lloyd J, Hutchison CW, Downey L, Stough C. 2001. The acute effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy normal subjects. Hum Psychopharmacol 16: 345-351.
145. Nathan PJ, Ricketts E, Wesnes K, Mrazek L, Greville W, Stough C. 2002. The acute nootropic effects of Ginkgo biloba in healthy older human subjects: a preliminary investigation. Hum Psychopharmacol 17: 45-49.
146. Nathan PJ, Tanner S, Lloyd J et al. 2004. Effects of a combined extract of Ginkgo biloba and Bacopa monniera on cognitive function in healthy humans. Hum Psychopharmacol 19: 91-96.
147. Oliva I, Gonzalez-Trujano ME, Arrieta J, Enciso-Rodriguez R, Navarrete A. 2004. Neuropharmacological profile of hydroalcohol extract of Valeriana edulis ssp. procera roots in mice. Phytother Res 18: 290-296.
148. Padma TV. 2005. Ayurveda. Nature 436: 486.
149. Pan HP. 2005. Progress in studies of pharmacological activities and clinical applications of preparations of dried leaf of Ginkgo biloba. Zhongguo Zhong Yao Za Zhi 30: 93-96.
150. Pawar R, Gopalakrishnan C, Bhutani KK. 2001. Dammarane triterpene saponin from Bacopa monniera as the superoxide inhibitor in polymorphonuclear cells. Planta Med 67: 752-754.
151. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. 2000. Indinavir concentrations and St. John's wort [Letter]. Lancet 355: 547-548.
152. Pittler MH, Ernst E. 2000. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharmacol 20: 84-89.
153. Poyares DR, Guilleminault C, Ohayon MM, Tufik S. 2002. Can valerian improve the sleep of insomniacs after benzodiazepine withdrawal? Prog Neuropsychopharmacol Biol Psychiatry 26: 539-545.
154. Rai D, Bhatia G, Palit G, Pal R, Singh S, Singh HK. 2003. Adaptogenic effect of Bacopa monniera (Brahmi). Pharmacol Biochem Behav 75: 823-830.
155. Rao CHV, Sairam K, Goel RK. 2000. Experimental evaluation of Bacopa monniera on rat gastric ulceration and secretion. Indian J Physiol Pharmacol 44: 435-441.
156. Re L, Corneli C, Sturani E et al. 2003. Effects of Hypericum extract on the acetylcholine release: a loose patch clamp approach. Pharmacol Res 48: 55-60.
157. Rodriguez-Landa JF, Contreras CM. 2003. A review of clinical and experimental observations about antidepressant actions and side effects produced by Hypericum perforatum extracts. Phytomedicine 10: 688-699.
158. Rohini G, Sabitha KE, Devi CS. 2004. Bacopa monniera Linn. extract modulates antioxidant and marker enzyme status in fibrosarcoma bearing rats. Indian J Exp Biol 42: 776-780.
159. Roodenrys S, Booth D, Bulzomi S, Phipps A, Micallef C, Smoker J. 2002. Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology 27: 279-281.
160. Roz N, Rehavi M. 2004. Hyperforin depletes synaptic vesicles content and induces compartmental redistribution of nerve ending monoamines. Life Sci 75: 2841-2850.
161. Ruschitzka F, Meier PJ, Turina M, Lüscher TF, Noll G. 2000. Acute heart transplant rejection due to Saint John's wort. Lancet 355: 548-549.
162. Russo A, Borrelli F. 2005. Bacopa monniera, a reputed nootropic plant: an overview. Phytomedicine 12: 305-317.
163. Russo A, Borrelli F, Campisi A, Acquaviva R, Raciti G, Vanella A. 2003b. Nitric oxide-related toxicity in cultured astrocytes: effect of Bacopa monniera. Life Sci 73: 1517-1526.
164. Russo A, Izzo AA, Borrelli F, Renis M, Vanella A. 2003a. Free radical scavenging capacity and protective effect of Bacopa monniera L. on DNA damage. Phytother Res 17: 870-875.
165. Sairam K, Dorababu M, Goel RK, Bhattacharya SK. 2002. Antidepressant activity of standardized extract of Bacopa monniera in experimental models of depression in rats. Phytomedicine 9: 207-211.
166. Sairam K, Rao CV, Babu MD, Goel RK. 2001. Prophylactic and curative effects of Bacopa monniera in gastric ulcer models. Phytomedicine 8: 423-430.
167. Sairam K, Rao CV, Goel RK. 2001 c. Effect of Convolvulus pluricaulis Chois on gastric ulceration and secretion in rats. Indian J Exp Biol 39: 350-354.
168. Santillos H. 1991. Natural Healing with Herbs. Hohn Press: Prescott, Arizona.
169. Santos MS, Ferreira F, Faro C et al. 1994c. The amount of GABA present in aqueous extracts of valerian is sufficient to account for [3H]GABA release in synaptosomes. Planta Med 60: 475-476.
170. Schellenberg R, Sauer S, Abourashed EA, Koetter U, Brattstrom A. 2004. The fixed combination of valerian and hops (Ze91019) acts via a central adenosine mechanism. Planta Med 70: 594-597.
171. Schultz OE, Mueller F. 1960. Investigations on valerian active substances with the Haffner test. Arzneimittelforschung 10: 78-88.
172. Schulz V. 2000. Incidence and clinical relevance of the interactions and side effects of Hypericum preparations. Perfusion 13: 486-494.
173. Schulz V. 2003a. Ginkgo extract or cholinesterase inhibitors in patients with dementia: what clinical trials and guidelines fail to consider. Phytomedicine 10: 74-79.
174. Shankar G, Singh HK. 2000. Anxiolytic profile of standardized Brahmi extract. Indian J Pharmacol 32: 152.
175. Shanmugasundaram ER, Akbar GK, Shanmugasundaram KR. 1991. Brahmighritham, an Ayurvedic herbal formula for the control of epilepsy. J Ethnopharmacol 33: 269-276.
176. Sharma R, Chaturvedi C, Tewari PV. 1987. Efficacy of Bacopa monniera in revitalizing intellectual functions in children. J Res Educ Indian Med 1: 12.
177. Shaughnessy F. 2002. Ease anxiety with shankhpushpi: Ayurvedic doctors prefer this mood-soother over kava-kava - Herb Brief. Natural Health Sept.: 1 as available on http://www.findarticles.com/p/articles/mi_m0NAH/is_7_32/ ai_91563259
178. Shinomiya K, Fujimura K, Kim Y, Kamei C. 2005a. Effects of valerian extract on the sleep-wake cycle in sleep-disturbed rats. Acta Med Okayama 59: 89-92.
179. Shinomiya K, Inoue T, Utsu Y et al. 2005b. Effects of kava-kava extract on the sleep-wake cycle in sleep-disturbed rats. Psychopharmacology 180: 564-569.
180. Shukia B, Khanna NK, Godhwani JL. 1987. Effect of Brahmi Rasayan on the central nervous system. J Ethnopharmacol 21: 65-74.
181. Sierpina VS, Wollschlaeger B, Blumenthal M. 2003. Ginkgo biloba. Am Fam Physician 68: 923-926.
182. Silva BA, Dias AC, Ferreres F, Malva JO, Oliveira CR. 2004. Neuroprotective effect of H. perforatum extracts on beta-amyloid-induced neurotoxicity. Neurotox Res 6: 119-130.
183. Singh HK, Dhawan BN. 1982. Effect of Bacopa monniera Linn. (brahmi) extract on avoidance responses in rat. J Ethnopharmacol 5: 205-214.
184. Singh HK, Dhawan BN. 1992. Drugs affecting learning and memory. In Lectures in Neurobiology, Tandon PN, Bijiani V, Wadhwa S (eds), vol. 1. Wiley Eastern: New Delhi, 189-207.
185. Singh HK, Dhawan BN. 1997. Neuropsychopharmacological effects of the Ayurvedic nootropic Bacopa monniera Linn (Brahmi). Indian J Pharmacol 29: S359-S365.
186. Singh HK, Shanker G, Patnaik GK. 1996. Neuropharmacological and anti-stress effects of bacosides: a memory enhancer. Indian J Pharmacol 28: 47.
187. Singh HK, Rastogi RP, Srimal RC, Dhawan BN. 1988. Effect of bacosides A and B on avoidance responses in rats. Phytothey Res 2: 70-75.
188. Singh RH, Singh L. 1980. Studies on the anti-anxiety effect of the medyha rasayana drug Brahmi (Bacopa monniera Wettst.). Res Ayur Siddha 1: 133-148.
189. Singh S, Eapen S, D'Souza SF. 2006. Cadmium accumulation and its influence on lipid peroxidation and antioxidative system in an aquatic plant, Bacopa monnieri L. Chemosphere 62: 233-246.
190. Singh YN. 2005. Potential for interaction of kava and St. John's wort with drugs. J Ethnopharmacol 100: 108-113.
191. Singh YN, Singh NN. 2002. Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs 16: 731-743.
192. Smith DB. 1991. Cognitive effects of anti-epileptic drugs. Adv Neurol 55: 197-212.
193. Smith JV, Luo Y. 2003. Elevation of oxidative free radicals in Alzheimer's disease models can be attenuated by Ginkgo biloba extract EGb 761. J Alzheimers Dis 5: 287-300.
194. Smith KK, Dharmaratne HR, Feltenstein MW et al. 2001. Anxiolytic effects of kava extract and kavalactones in the chick social separation-stress paradigm. Psychopharmacology 155: 86-90.
195. Sparreboom A, Cox MC, Acharya MR, Figg WD. 2004. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 22: 2489-2503.
196. Stackman RW, Eckenstein F, Frei B, Kulhanek D, Nowlin J, Quinn JF. 2003. Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Exp Neurol 184: 510-520.
197. Stevinson C, Ernst E. 2000. A pilot study of Hypericum perforatum for the treatment of premenstrual syndrome. Br J Obstet Gynaecol 107: 870-876.
198. Stough C, Lloyd J, Clarke J et al. 2001. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology (Berl) 156: 481-484.
199. Sumathi T, Nayeem M, Balakrishna K, Veluchamy G, Devaraj SN. 2002a. Alcoholic extract of 'Bacopa monniera' reduces the in vitro effects of morphine withdrawal in guinea-pig ileum. J Ethnopharmacol 82: 75-81.
200. Sumathy T, Govindasamy S, Balakrishna K, Veluchamy G. 2002b. Protective role of Bacopa monniera on morphine-induced brain mitochondrial enzyme activity in rats. Fitoterapia 73: 381-385.
201. Sumathy T, Subramanian S, Govindasamy S, Balakrishna K, Veluchamy G. 2001. Protective role of Bacopa monniera on morphine induced hepatotoxicity in rats. Phytother Res 15: 643-645.
202. Taibi DM, Bourguignon C, Taylor AG. 2004. Valerian use for sleep disturbances related to rheumatoid arthritis. Holist Nurs Pract 18: 120-126.
203. Teschke R, Gaus W, Loew D. 2003. Kava extracts: safety and risks including rare hepatotoxicity. Phytomedicine 10: 440-446.
204. Thies PW, Funke S. 1966. On the active ingredients in baldrian. 1. Detection and isolation of isovalerian acid esters with sedative effect from roots and rhizomes of various valerian and kentranthus species. Tetrahedron Lett 11: 1155-1162.
205. Thompson R, Ruch W, Hasenohrl RU. 2004. Enhanced cognitive performance and cheerful mood by standardized extracts of Piper methysticum (Kava-kava). Hum Psychopharmacol 19: 243-250.
206. Tierra M. 1990. The Way of Herbs. Pocket Books: New York, 177-178.
207. Treiber K, Singer A, Henke B, Muller WE. 2005. Hyperforin activates nonselective cation channels (NSCCs). Br J Pharmacol 145: 75-83.
208. Trevena L. 2004. Sleepless in Sydney - is valerian an effective alternative to benzodiazepines in the treatment of insomnia? ACP J Club 141: A14-A16.
209. Tripathi YB, Chaurasia S, Tripathi E, Upadhyay A, Dubey GP. 1996. Bacopa monniera Linn. as an antioxidant: mechanism of action. Indian J Exp Biol 34: 523-526.
210. Trofimiuk E, Walesiuk A, Braszko JJ. 2005. St John's wort (Hypericum perforatum) diminishes cognitive impairment caused by the chronic restraint stress in rats. Pharmacol Res 51: 239-246.
211. Ulbricht C, Basch E, Boon H et al. 2005. Safety review of kava (Piper methysticum) by the Natural Standard Research Collaboration. Expert Opin Drug Saf 4: 779-794.
212. Uphof JC. 1968. The Dictionary of Economic Plants, vol. 62. Verlag von J Cramer: New York.
213. van Dongen MC, van Rossum E, Kessels AG, Sielhorst HJ, Knipschild PG. 2000. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J Am Geriatr Soc 48: 1183-1194.
214. Van Veen AG. 1938. (Over the bedwelmende stof vit de kawakawa of wati-plant) (Piper methysticum). Geneeskundig tijdschrift voor Nederlandsch-Indie 78: 194-195.
215. Verotta L. 2003. Hypericum perforatum, a source of neuroactive lead structures. Curr Top Med Chem 3: 187-201.
216. Vitiello B, Shader RI, Parker CB et al. 2005. Hyperforin plasma level as a marker of treatment adherence in the National Institutes of Health Hypericum Depression Trial. J Clin Psychopharmacol 25: 243-249.
217. Vohora D, Pal SN, Pillai KK. 2000. Protection from phenytoin-induced cognitive deficit by Bacopa monniera, a reputed Indian nootropic plant. J Ethnopharmacol 71: 383-390.
218. Warburton DM. 1988. Clinical Psychopharmacology of Ginkgo biloba extract. In Rokan (Ginkgo biloba): Recent Results in Pharmacology and Clinic, Flmfgeld EW (ed.), Springer Verlag, Berlin-Heidelberg, 327-345.
219. Weichel O, Hilgert M, Chatterjee SS, Lehr M, Klein J. 1999. Bilobalide, a constituent of Ginkgo biloba, inhibits NMDA-induced phospholipase A2 activation and phospholipid breakdown in rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 360: 609-615.
220. Wettstein A. 2000. Cholinesterase inhibitors and Gingko extracts - are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration. Phytomedicine 6: 393-401.
221. Wheatley D. 2001a. Kava and valerian in the treatment of stress-induced insomnia. Phytother Res 15: 549-551.
222. Wheatley D. 2001b. Stress-induced insomnia treated with kava and valerian: singly and in combination. Hum Psychopharmacol 16: 353-356.
223. Wheatley D. 2005. Medicinal plants for insomnia: a review of their pharmacology, efficacy and tolerability. J Psychopharmacol 19: 414-421.
224. Widy-Tyszkiewicz E, Piechal A, Joniec I, Blecharz-Klin K. 2002. Long term administration of Hypericum perforatum improves spatial learning and memory in the water maze. Biol Pharm Bull 25: 1289-1294.
225. Williams B, Watanabe CM, Schultz PG, Rimbach G, Krucker T. 2004. Age-related effects of Ginkgo biloba extract on synaptic plasticity and excitability. Neurobiol Aging 25: 955-962.
226. Witte S, Loew D, Gaus W. 2005. Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. Phytother Res 19: 183-188.
227. Yao ZX, Han Z, Drieu K, Papadopoulos V. 2004. Ginkgo biloba extract (Egb 761) inhibits beta-amyloid production by lowering free cholesterol levels. J Nutr Biochem 15: 749-756.
228. Yuan CS, Mehendale S, Xiao Y, Aung HH, Xie JT, Ang-Lee MK. 2004. The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth Analg 98: 353-358.
229. Yue QY, Bergquist C, Gerden B. 2000. Safety of St. John's wort (Hypericum perforatum) [Letter]. Lancet 355: 576-577.
230. Zanoli P. 2004. Role of hyperforin in the pharmacological activities of St. John's Wort. CNS Drug Rev 10: 203-218.
231. Zanoli P, Rivasi M, Baraldi C, Baraldi M. 2002. Pharmacological activity of hyperforin acetate in rats. Behav Pharmacol 13: 645-651.
232. Z'Brun A. 1995. Ginkgo - myth and reality. Schweiz Rundsch Med Prax 84: 1-6.
233. Zhang ZJ. 2004. Therapeutic effects of herbal extracts and constituents in animal models of psychiatric disorders. Life Sci 75: 1659-1699.
234. Ziegler G, Ploch M, Miettinen-Baumann A, Collet W. 2002. Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia - a randomized, double-blind, comparative clinical study. Eur J Med Res 7: 480-486.
235. Zimmermann M, Colciaghi F, Cattabeni F, Di Luca M. 2002. Ginkgo biloba extract: from molecular mechanisms to the treatment of Alzheimer's disease. Cell Mol Biol (Noisy-le-grand) 48: 613-623.
236. Zou L, Henderson GL, Harkey MR, Sakai Y, Li A. 2004. Effects of kava (Kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. Phytomedicine 11: 285-294.